The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma

被引：32

作者：

Brar, Gagandeep ^{[2
]}

Shah, Manish A. ^{[1
]}

机构：

[1] Weill Cornell Med New York Presbyterian Hosp, Div Hematol & Med Oncol, 1305 York Ave,Room Y1247, New York, NY 10021 USA

[2] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2019年 / 12卷

关键词：

checkpoint blockade; gastric cancer; immunotherapy; RANDOMIZED PHASE-III; LIGAND; EXPRESSION; CLINICAL-SIGNIFICANCE; IMMUNOHISTOCHEMISTRY ASSAY; 2ND-LINE THERAPY; DOUBLE-BLIND; CANCER; CHEMOTHERAPY; FLUOROURACIL; CISPLATIN;

D O I：

10.1177/1756284819869767

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have become standard treatment options in numerous tumor types. In this review, we discuss the current and evolving use of checkpoint blockade, focusing on the anti-PD-1 inhibitor, pembrolizumab, for use in advanced gastric and gastroesophageal cancers.

引用

页数：12

共 66 条

[41] High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation [J].

Mu, Chuan-Yong ;

Huang, Jian-An ;

Chen, Ying ;

Chen, Cheng ;

Zhang, Xue-Guang .

MEDICAL ONCOLOGY, 2011, 28 (03) :682-688

[42] Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial [J].

Muro, Kei ;

Chung, Hyun Cheol ;

Shankaran, Veena ;

Geva, Ravit ;

Catenacci, Daniel ;

Gupta, Shilpa ;

Eder, Joseph Paul ;

Golan, Talia ;

Le, Dung T. ;

Burtness, Barbara ;

McRee, Autumn J. ;

Lin, Chia-Chi ;

Pathiraja, Kumudu ;

Lunceford, Jared ;

Emancipator, Kenneth ;

Juco, Jonathan ;

Koshiji, Minori ;

Bang, Yung-Jue .

LANCET ONCOLOGY, 2016, 17 (06) :717-726

[43] PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma [J].

Nghiem, Paul T. ;

Bhatia, Shailender ;

Lipson, Evan J. ;

Kudchadkar, Ragini R. ;

Miller, Natalie J. ;

Annamalai, Lakshmanan ;

Berry, Sneha ;

Chartash, Elliot K. ;

Daud, Adil ;

Fling, Steven P. ;

Friedlander, Philip A. ;

Kluger, Harriet M. ;

Kohrt, Holbrook E. ;

Lundgren, Lisa ;

Margolin, Kim ;

Mitchell, Alan ;

Olencki, Thomas ;

Pardoll, Drew M. ;

Reddy, Sunil A. ;

Shantha, Erica M. ;

Sharfman, William H. ;

Sharon, Elad ;

Shemanski, Lynn R. ;

Shinohara, Michi M. ;

Sunshine, Joel C. ;

Taube, Janis M. ;

Thompson, John A. ;

Townson, Steven M. ;

Yearley, Jennifer H. ;

Topalian, Suzanne L. ;

Cheever, Martin A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (26) :2542-2552

[44] Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer [J].

Nomi, Takeo ;

Sho, Masayuki ;

Akahori, Takahiro ;

Hamada, Kaoru ;

Kubo, Atsushi ;

Kanehiro, Hiromichi ;

Nakamura, Shinji ;

Enomoto, Koji ;

Yagita, Hideo ;

Azuma, Miyuki ;

Nakajima, Yoshiyuki .

CLINICAL CANCER RESEARCH, 2007, 13 (07) :2151-2157

[45]

Noone AM., 2018, ACUTE MYELOID LEUKEM

[46] Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer [J].

Okines, A. F. C. ;

Norman, A. R. ;

McCloud, P. ;

Kang, Y. -K. ;

Cunningham, D. .

ANNALS OF ONCOLOGY, 2009, 20 (09) :1529-1534

[47] Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC) [J].

Pusztai, Lajos ;

Hofstatter, Erin Wysong ;

Chung, Gina G. ;

Horowitz, Nina Ruth ;

Lannin, Donald R. ;

Killelea, Brigid K. ;

Chagpar, Anees B. ;

DiGiovanna, Michael ;

Frederick, Courtney ;

Burello, Trisha ;

Harigopal, Malini .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[48] Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma [J].

Ralph, Christy ;

Elkord, Eyad ;

Burt, Deborah J. ;

O'Dwyer, Jackie F. ;

Austin, Eric B. ;

Stern, Peter L. ;

Hawkins, Robert E. ;

Thistlethwaite, Fiona C. .

CLINICAL CANCER RESEARCH, 2010, 16 (05) :1662-1672

[49] Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial [J].

Ribas, Antoni ;

Puzanov, Igor ;

Dummer, Reinhard ;

Schadendorf, Dirk ;

Hamid, Omid ;

Robert, Caroline ;

Hodi, F. Stephen ;

Schachter, Jacob ;

Pavlick, Anna C. ;

Lewis, Karl D. ;

Cranmer, Lee D. ;

Blank, Christian U. ;

O'Day, Steven J. ;

Ascierto, Paolo A. ;

Salama, April K. S. ;

Margolin, Kim A. ;

Loquai, Carmen ;

Eigentler, Thomas K. ;

Gangadhar, Tara C. ;

Carlino, Matteo S. ;

Agarwala, Sanjiv S. ;

Moschos, Stergios J. ;

Sosman, Jeffrey A. ;

Goldinger, Simone M. ;

Shapira-Frommer, Ronnie ;

Gonzalez, Rene ;

Kirkwood, John M. ;

Wolchok, Jedd D. ;

Eggermont, Alexander ;

Li, Xiaoyun Nicole ;

Zhou, Wei ;

Zernhelt, Adriane M. ;

Lis, Joy ;

Ebbinghaus, Scot ;

Kang, S. Peter ;

Daud, Adil .

LANCET ONCOLOGY, 2015, 16 (08) :908-918

[50] Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer [J].

Roach, Charlotte ;

Zhang, Nancy ;

Corigliano, Ellie ;

Jansson, Malinka ;

Toland, Grant ;

Ponto, Gary ;

Dolled-Filhart, Marisa ;

Emancipator, Kenneth ;

Stanforth, Dave ;

Kulangara, Karina .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (06) :392-397

← 1 2 3 4 5 6 7 →